Evidence board / study by study
Sermorelin Research: The GHRH(1-29) Evidence, Study by Study
Mechanism, the human GH/IGF-1 trials, pharmacokinetics, the analog comparisons, and the honest concerns — each panel one finding, each figure cited.
The short version
Sermorelin research is unusually quotable, so this page reads it as a board of figures. Sermorelin is the working front-end of GHRH (the brain's "make growth hormone" signal). In GH-deficient children it roughly doubled first-year growth speed [1]. In older men it pushed growth hormone and IGF-1 (the liver's growth signal) back toward young-adult levels [2]. It works fast and clears fast — minutes in the blood, but about three hours of raised growth hormone per dose [3]. Below, each finding gets its own panel, with the study and the numbers attached. None of it is dosing guidance.
Sermorelin mechanism of action
The sermorelin mechanism of action begins at one receptor. As the active 1-29 fragment of GHRH, it binds the GHRH receptor (GHRH-R), a class B G-protein-coupled receptor on the anterior pituitary's somatotrophs [11]. Binding activates the Gs / adenylate-cyclase / cAMP / protein kinase A cascade, raising intracellular cAMP and switching on PKA. Downstream, that drives GH gene transcription, pulsatile GH release, and a trophic (growth-promoting) effect on the somatotrophs themselves [11].
The released GH then raises hepatic IGF-1, and IGF-1 plus somatostatin feed back to restrain further GH release [11]. Because sermorelin acts upstream and leaves those brakes intact, it reinforces the natural pulsatile pattern rather than overriding it — the physiologic argument an editorial made for secretagogues over recombinant GH in adult GH insufficiency [4]. The full neuroregulation of GH secretion, including the GHRH, somatostatin, and ghrelin inputs, is detailed in a comprehensive Endocrine Reviews synthesis [11].
Does sermorelin work? The human GH/IGF-1 trials
The clearest efficacy evidence is in two populations. In a multicenter trial of prepubertal GH-deficient children, once-daily subcutaneous GHRH(1-29) accelerated linear growth: first-year height velocity rose from about 4.1 cm/year to roughly 7-8 cm/year, without excessive IGF-1 generation [1]. In healthy older men (mean 68), 0.5 mg and 1 mg subcutaneously twice daily for 14 days produced dose-related increases in 24-hour GH and IGF-1; after the high dose, those values no longer differed from young men, with no effect on fasting glucose [2].
Those are the established results. What remains open is long-term adult efficacy: an Annals of Internal Medicine editorial judged the use of GH secretagogues to prevent or treat the effects of aging "not yet ready for prime time" [5].
Sermorelin half-life: short by design
The sermorelin half-life is one of its best-characterized properties. In 30 healthy men, intravenous GHRH(1-29)NH2 elicited GH release at doses as low as 0.25 mcg/kg, peaking at 1-2 mcg/kg; the plasma half-life sits around 10-12 minutes, yet a single dose elevated serum GH for about 3 hours [3]. Intranasal bioavailability was only 3-5% [3].
That clearance is the engineering problem the next generation of analogs solved — see sermorelin vs CJC-1295 for the DAC and PEGylation half-life-extension chemistry [10].
What studies report over time
Reframed from anecdotal "sermorelin before and after" reports, the measured trajectory is this. Biochemically, GHRH(1-29) raises GH within minutes and holds it elevated for about 3 hours [3]. Measurable IGF-1 and body-composition changes developed over weeks to months in the studied populations — dose-related 24-hour GH and IGF-1 increases after 14 days in older men [2], and in the GHRH-analog cognition trial, a 117% IGF-1 rise and a 7.4% reduction in body fat over 20 weeks [6]. In GH-deficient children, first-year height velocity rose from ~4.1 to 7-8 cm/year [1]. These are trial outcomes over defined study periods, not a treatment timeline anyone should expect.
Sermorelin vs Ipamorelin: GHRH analog vs GHRP
Sermorelin vs ipamorelin is a comparison of two different mechanisms, not two versions of one. Sermorelin is a GHRH-receptor analog — it acts on the GHRH receptor on somatotrophs [11]. Ipamorelin is a growth-hormone-releasing peptide (GHRP): it acts on the ghrelin / GH-secretagogue receptor, a separate receptor system [11]. Both raise GH, but through distinct upstream signals, which is why the two classes are studied — and sometimes discussed together — as complementary rather than interchangeable. The neuroregulation review lays out how the GHRH, somatostatin, and ghrelin inputs converge on GH secretion [11]. This site documents the GHRH side of that picture.
Sermorelin among GHRH analogs (tesamorelin)
Within the GHRH-analog family, sermorelin vs tesamorelin marks the line between the native fragment and a stabilized derivative. Tesamorelin is a stabilized synthetic GHRH analog (approved for HIV-associated lipodystrophy) used in much of the body-composition and cognition literature cited here as drug-class evidence — including the controlled cognition trial that raised IGF-1 117% and lowered body fat 7.4% over 20 weeks [6]. Sermorelin is the unmodified GHRH(1-29); tesamorelin is engineered for stability. The 2025 Nature Reviews Endocrinology review situates both within the broader account of GHRH agonists and antagonists in health and disease [12].
Sermorelin and sleep
GHRH has a genuine physiologic role in promoting slow-wave sleep, and slow-wave sleep is when most nocturnal GH is released [11] — the rationale behind bedtime dosing in the studies. That sleep-promoting effect is also blunted with age. The neuroregulation literature treats GHRH's sleep-endocrine effects as time-of-day dependent [11]. Individual sleep experiences vary and are not equivalent to the controlled sleep-EEG findings.
Why bedtime dosing is studied
The body's largest natural GH pulse occurs during early slow-wave sleep, so studies typically dosed GHRH(1-29) at bedtime to reinforce that nocturnal pulse [11]. The sleep-endocrine effects of GHRH depend on the timing of administration [11]. This explains the study rationale; it is not a personal dosing instruction.
Sermorelin and fat loss
GHRH-axis stimulation can change body composition in studies: the related GHRH analog tesamorelin reduced visceral fat versus placebo in its trial program, and the 20-week cognition trial recorded body fat dropping 7.4% [6]. Pulsatile GH also participates in regulating fasting lipolysis [11]. Evidence for sermorelin specifically as a fat-loss agent in healthy adults is limited, and body-composition marketing outruns the data.
Is sermorelin effective for weight loss?
The body-composition literature centers on the stabilized analog tesamorelin reducing visceral adipose tissue [6], not on sermorelin as a weight-loss drug. Anti-aging and body-composition marketing outpaces the actual evidence for GHRH(1-29) in healthy adults, and an Annals editorial cautioned against treating GH secretagogues as proven aging interventions [5].
Sermorelin and muscle
The muscle evidence is indirect. GHRH-axis stimulation raises GH and IGF-1 [2], and reviews discuss GH/IGF-1 modulation as a candidate strategy against age-related muscle loss (sarcopenia) [12]. No controlled trial shows sermorelin itself builds muscle in healthy adults; the muscle-building claims outrun the data.
Sermorelin and IGF-1
Sermorelin raises IGF-1 in the studied populations. GHRH(1-29) raised IGF-1 dose-dependently in older men, with high-dose values no longer differing from young men [2], and GH-secretagogue treatment raised serum IGF-1 in older subjects [6]. Because IGF-1 rises through the body's own feedback-regulated GH release, the increase stayed within a physiologic range in these trials [6][11].
Reported and theoretical concerns
On sermorelin side effects, the trial record is reassuring but not blank. The most common findings in trials were mild, transient injection-site reactions and reversible anti-GHRH antibodies that did not interfere with growth [1]. Long-term GHRH-analog dosing in older subjects sometimes showed mild glucose-tolerance changes or transient hyperlipidemia.
Two cautions are theoretical but real. Because GH and IGF-1 are mitogenic — they drive cell growth — chronically raising them carries a theoretical oncologic caution for any GH-axis intervention, even one that works through feedback-regulated pulsatile secretion [11]. And GH secretagogues, including GHRH analogs, are prohibited in sport by WADA under hormone and metabolic modulators (S2), with dedicated detection methods in place.